GFM
SLDB icon

GF Fund Management’s Solid Biosciences SLDB Stock Holding History

GF Fund Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Buy
1,946
+207
+12% +$1.57K ﹤0.01% 486
2026
Q1 		$12.5K Buy
1,739
+209
+14% +$1.34K ﹤0.01% 540
2025
Q4 		$8.63K Sell
1,530
-145
-9% -$786 ﹤0.01% 588
2025
Q3 		$10.3K Buy
1,675
+684
+69% +$4K ﹤0.01% 555
2025
Q2 		$4.83K Hold
991
– – ﹤0.01% 629
2025
Q1 		$3.67K Buy
991
+152
+18% +$651 ﹤0.01% 634
2024
Q4 		$3.36K Buy
+839
New +$4.61K ﹤0.01% 626

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GF Fund Management's SLDB Position: Q2 2026 in Review

GF Fund Management increased its Solid Biosciences (SLDB) stake by 12% in Q2 2026, buying an estimated $1.57K and bringing the position to 1,946 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #486.

GF Fund Management first reported a position in SLDB in Q4 2024 and has held it in 7 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • GF Fund Management held 1,946 shares of Solid Biosciences worth $19.4K as of Q2 2026.
  • GF Fund Management bought 207 Solid Biosciences shares in Q2 2026, an estimated $1.57K.
  • Solid Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #486 holding.
  • GF Fund Management first reported a position in Solid Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.